Dyne Therapeutics (DYN) EBIT (2019 - 2026)
Dyne Therapeutics (DYN) recorded quarterly EBIT of -$125.3 million in Q1 2026, down 7.88% quarter-over-quarter from -$116.1 million in Q4 2025, and down 2.37% on a YoY basis from -$128.3 million in Q1 2025.
Dyne Therapeutics (DYN) EBIT (2019 - 2026) Analysis & Trends
Dyne Therapeutics' EBIT history runs 8 years deep, the most recent figure standing at -$125.3 million for Q1 2026.
- In Q1 2026, EBIT fell 2.37% year-over-year to -$125.3 million; the TTM figure through Mar 2026 stood at -$471.1 million (down 18.66% YoY), while the FY2025 annual figure was -$468.2 million, down 36.15% from the prior year.
- EBIT was -$125.3 million for Q1 2026 at Dyne Therapeutics, down from -$116.1 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$35.8 million in Q1 2022 to a low of -$125.3 million in Q1 2026.
- Historically, EBIT has averaged -$79.4 million across 5 years, with a median of -$69.2 million in 2024.
- The sharpest annual moves came in 2022 and 2025: EBIT grew 22.74% in 2022, then slumped 76.95% in 2025.
- A 5-year view of EBIT shows it stood at -$40.1 million in 2022, then sank by 68.61% to -$67.7 million in 2023, then tumbled by 43.46% to -$97.1 million in 2024, then slipped by 19.59% to -$116.1 million in 2025, then dropped by 7.88% to -$125.3 million in 2026.
- The last three EBIT figures came in at -$125.3 million (Q1 2026), -$116.1 million (Q4 2025), and -$113.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -65.83 Mn |
| 10 | Dyne Therapeutics | 3.00 Bn | 3.00 Bn | - | -125.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -125.28 Mn |
| Dec 31, 2025 | -116.13 Mn |
| Sep 30, 2025 | -113.89 Mn |
| Jun 30, 2025 | -115.79 Mn |
| Mar 31, 2025 | -122.37 Mn |
| Dec 31, 2024 | -97.11 Mn |
| Sep 30, 2024 | -105.57 Mn |
| Jun 30, 2024 | -71.96 Mn |
| Mar 31, 2024 | -69.16 Mn |
| Dec 31, 2023 | -67.69 Mn |
| Sep 30, 2023 | -62.27 Mn |
| Jun 30, 2023 | -66.74 Mn |
| Mar 31, 2023 | -45.46 Mn |
| Dec 31, 2022 | -40.15 Mn |
| Sep 30, 2022 | -42.28 Mn |
| Jun 30, 2022 | -52.76 Mn |
| Mar 31, 2022 | -35.78 Mn |
| Dec 31, 2021 | -51.96 Mn |
| Sep 30, 2021 | -42.77 Mn |
| Jun 30, 2021 | -30.17 Mn |